Drug Profile
Research programme: eye disorders therapy - Dharmacon/Alcon
Alternative Names: RNAi-based therapy for eye disordersLatest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Alcon; Dharmacon
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 03 Jul 2007 No development reported - Preclinical for Eye disorders in USA (unspecified route)
- 19 Oct 2005 Preclinical trials in Eye disorders in USA (unspecified route)